Compare Amgen, Inc. (AMGN) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Bitwise Crypto Industry Innovators ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Bitwise Crypto Industry Innovators ETF trades at $22.36. The key difference: Amgen, Inc. pays a 2.43% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BITQ | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Crypto-linked |
52-Week High | $417.20 | $30.43 |
52-Week Low | $271.18 | $16.74 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BITQ trades at $22.88, up 1.42% today, but faces strong technical headwinds with 17 sell signals versus 0 buy signals across moving averages and oscillators. The stock shows bearish momentum with key resistance at $23 and support at $22. Financial metrics remain unavailable in current data, requiring verification through SEC filings.
The technical outlook appears bearish with weak momentum indicators. Investment opportunity depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and lack of visible fundamental support until financial disclosures are updated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
